Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | NRAS | P01111 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187139 | 0.89 | FGFR1 (0.45) | S1PR1FGFR1FGFR2FGFR3NTRK1 | |
| SCHEMBL4189829 | 0.85 | FGFR3 (0.39) | FGFR1FGFR2FGFR3MAPK1KDR | |
| SCHEMBL4185266 | 0.83 | KDM4E (0.41) | FGFR1FGFR2FGFR3CSF1RMAPK1 | |
| SCHEMBL4177971 | 0.83 | PRMT5 (0.39) | S1PR1FGFR1FGFR2FGFR3JAK2 | |
| SCHEMBL13929793 | 0.82 | PLAU (0.45) | FGFR1FGFR2FGFR3CSF1RKDR | |
| SCHEMBL4177973 | 0.81 | FGFR1 (0.41) | FGFR1FGFR2FGFR3JAK2JAK1 | |
| SCHEMBL4182669 | 0.80 | PGK1 (0.51) | MAPK1 | |
| SCHEMBL4177982 | 0.78 | ACHE (0.40) | PDPK1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4178307 | 0.73 | FGFR1 (0.39) | FGFR1FGFR2FGFR3MAPK1KDR | |
| SCHEMBL298911 | 0.73 | PLAU (0.44) | FGFR1FGFR2FGFR3CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | S1PR1 1971/4885FGFR1 4085/4885FGFR2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.